rabeprazole + mosapride

Rabeprazole + mosapride is a fixed-dose oral combination of two pharmaceutical agents used primarily for the management of gastroesophageal reflux disease (GERD), peptic ulcer disease, and other gastrointestinal disorders such as functional dyspepsia and irritable bowel syndrome. Rabeprazole is a proton pump inhibitor that suppresses gastric acid secretion by inhibiting the H+/K+ ATPase enzyme in gastric parietal cells. Mosapride is a prokinetic agent that acts as a selective 5-HT4 receptor agonist, enhancing gastrointestinal motility by stimulating acetylcholine release in the enteric nervous system. The combination provides both acid suppression (from rabeprazole) and improved gastric emptying/motility (from mosapride), offering symptomatic relief for patients with acid-related disorders who may also have delayed gastric emptying or dysmotility[1][2][3][4][7].

Other names

mosapride + rabeprazolemosapride and rabeprazole combination therapy